AccessibilityHelp

Most Active Stocks Daily Stock Gainers Daily Stock Losers

Most Active Stocks Daily Stock Gainers Daily Stock Losers

Brian Orelli, PhD

TMFBiologyFool

Dr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007.

Articles by Brian Orelli, PhD — Page 3

Some_Prominent_Doctors_Continue_to_Shun_Biogen’s_Alzheimer’s_Drug[1]

May 9, 2021 by Brian Orelli, PhD and Keith Speights

Some Prominent Doctors Continue to Shun Biogen's Alzheimer's Drug

Even if the FDA approves the drug, it could be hard to sell with key opinion leaders coming out against the therapy.

Is_Vaccine-Maker_Vaxart_Worth_Holding_From_Here[1]

May 9, 2021 by Brian Orelli, PhD and Keith Speights

Is Vaccine Maker Vaxart Worth Holding From Here?

As with most investment decisions, whether to hold depends on the situation. Here are some things to think about.

Why_Is_GlaxoSmithKline_Selling_Its_Income_Stream_to_Royalty_Pharma[1]

May 9, 2021 by Brian Orelli, PhD and Keith Speights

Why Is GlaxoSmithKline Selling Its Income Stream to Royalty Pharma?

Apparently, up-front capital is better than royalties on drugs the pharma doesn't have control over.

How_Much_is_BioNTech’s_Increased_Vaccine_Production_Really_Worth[1]

May 9, 2021 by Brian Orelli, PhD and Keith Speights

How Much Is BioNTech's Increased Vaccine Production Really Worth?

Additional capacity may not be as valuable as the initial doses.

Is_BioNTech_More_Than_a_One-Trick_Pony[1]

May 9, 2021 by Brian Orelli, PhD and Keith Speights

Is BioNTech More Than a One-Trick Pony?

The German drugmaker has additional drugs in its pipeline beyond its coronavirus vaccine.

6_Months_Later,_Pfizer_and_BioNTech’s_Vaccine_Data_Continues_to_Impress[1]

May 9, 2021 by Brian Orelli, PhD and Keith Speights

6 Months Later, Pfizer and BioNTech's Vaccine Data Continues to Impress

Investors should be focused on long-term data.

Should_Teladoc_Be_Worried_About_Grand_Rounds_and_Doctors_on_Demands_Merger[1]

May 7, 2021 by Brian Orelli, PhD and Keith Speights

Should Teladoc Be Worried About the Grand Rounds and Doctors on Demands Merger?

There should be room for multiple winners in the telehealth space.

Should_Investors_Be_Worried_About_Clover_Health’s_Class_Action_Lawsuits[1]

May 7, 2021 by Brian Orelli, PhD and Keith Speights

Should Investors Be Worried About Clover Health's Class Action Lawsuits?

Long-term investors should take a wait-and-see attitude.

Want to Make Money in Biotech? Do This First

May 7, 2021 by Brian Orelli, PhD and Keith Speights

Want to Make Money in Biotech? Do This First

Keeping track of upcoming events is important.

Bristol_Myers_Squibb’s_Latest_Data_Could_Help_the_Pharma_Leapfrog_Rival_Merck[1]

May 3, 2021 by Brian Orelli, PhD and Keith Speights

Bristol Myers Squibb's Latest Data Could Help the Pharma Leapfrog Rival Merck

LAG-3 is the new PD-1.

This_Data_Could_Accelerate_Bristol_Myers_Squibb’s_Cancer_Drug_Opportunity[1]

May 2, 2021 by Brian Orelli, PhD and Keith Speights

This Data Could Accelerate Bristol Myers Squibb's Cancer Drug Opportunity

Investors will have to wait for the full data set to see how much the drug could really help cancer patients.

What_Investors_Need_to_Know_About_This_$419,500_CAR_T_Cancer_Treatment[1]

May 1, 2021 by Brian Orelli, PhD and Keith Speights

What Investors Need to Know About This $419,500 CAR-T Cancer Treatment

Abecma is on the market.

CureVac’s_Vaccine_Might_Protect_Against_the_South_African_Variant[1]

May 1, 2021 by Brian Orelli, PhD and Keith Speights

CureVac's Vaccine Might Protect Against the South African Variant

The promising data in mice needs to translate into humans.

Beyond_a_Vaccine,_Pfizer_Looks_to_Treat_COVID-19[1]

Apr 27, 2021 by Brian Orelli, PhD and Keith Speights

Beyond a Vaccine, Pfizer Looks to Treat COVID-19

Don't forget about treatments.

Who_Are_Amazon_s_Ideal_Telehealth_Customer[1]

Apr 19, 2021 by Brian Orelli, PhD and Keith Speights

Who Are Amazon's Ideal Telehealth Customers?

The consumer-focused company is focused on offering the service to other employers.

Is_$500_Million_Enough_for_a_Biotech-Focused_SPAC[1]

Apr 18, 2021 by Brian Orelli, PhD and Keith Speights

Is $500 Million Enough for a Biotech-Focused SPAC?

The eventual merger could involve a PIPE to help boost the capital available to the private company.

Novavax_Is_Missing_Out_On_a_Big_Deal[1]

Apr 17, 2021 by Brian Orelli, PhD and Keith Speights

Novavax Is Missing Out on a Big Deal

The European Union could bolster the biotech's coronavirus revenue.

AstraZeneca’s_Vaccine_Data_Is_Still_Good_Enough_for_U.S._Authorization[1]

Apr 17, 2021 by Brian Orelli, PhD and Keith Speights

AstraZeneca's Vaccine Data Is Still Good Enough for U.S. Authorization

An Emergency Use Authorization from the FDA should happen soon.

A_Star-Laden_Biotech_SPAC_Worth_Considering[1]

Apr 17, 2021 by Brian Orelli, PhD and Keith Speights

A Star-Laden Biotech SPAC Worth Considering

This healthcare-focused SPAC checks all the boxes -- except the company it plans to merge with.

Which_Companies_Will_Be_Most_Hurt_by_Amazon_s_Move_Into_Healthcare[1]

Apr 14, 2021 by Brian Orelli, PhD and Keith Speights

Which Companies Will Be Most Hurt by Amazon's Move Into Healthcare?

The conglomerate has moved into prescription drug distribution and is looking at options for telehealth medicine.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services